vatalanib has been researched along with arginyl-glycyl-aspartic acid in 2 studies
| Studies (vatalanib) | Trials (vatalanib) | Recent Studies (post-2010) (vatalanib) | Studies (arginyl-glycyl-aspartic acid) | Trials (arginyl-glycyl-aspartic acid) | Recent Studies (post-2010) (arginyl-glycyl-aspartic acid) |
|---|---|---|---|---|---|
| 276 | 42 | 98 | 4,556 | 17 | 1,799 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kéri, G; Kok, RJ; Lacombe, M; Molema, G; Orfi, L; Poelstra, K; Schaapveld, RQ; Temming, K | 1 |
| Asgeirsdottir, SA; Kéri, G; Kok, RJ; Lacombe, M; Molema, G; Moorlag, HE; Orfi, L; Poelstra, K; Temming, K | 1 |
2 other study(ies) available for vatalanib and arginyl-glycyl-aspartic acid
| Article | Year |
|---|---|
Rational design of RGD-albumin conjugates for targeted delivery of the VEGF-R kinase inhibitor PTK787 to angiogenic endothelium.
Topics: Albumins; Drug Design; Endothelium, Vascular; Neovascularization, Physiologic; Oligopeptides; Phthalazines; Pyridines; Receptors, Vascular Endothelial Growth Factor; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2006 |
Targeting of the VEGF-kinase inhibitor PTK787 to angiogenic vasculature using RGD-equipped albumin carrier molecules.
Topics: Albumins; Binding, Competitive; Cells, Cultured; Drug Carriers; Drug Delivery Systems; Endothelial Cells; Humans; Oligopeptides; Phthalazines; Pyridines; Vascular Endothelial Growth Factor A | 2006 |